Comparative Study of Hepatic and Renal Markers in Treatment of Kala-azar with I.V. Amphotericin B and Oral Miltefosine

This study was designed to compare the hepatic and renal markers in treatment with two most commonly used drugs I.V. Amphotericin B and oral Miltefosine in diagnosed cases of KALA-AZAR. This was an 'OBSERVATIONAL' and 'CROSS-SECTIONAL' study. This study was conducted on two groups each had fifty patients. I.V. Amphotericin B and oral Miltefosine were given to group A and B respectively. Rise of serum bilirubin was not significant (p>0.05) in either group. Mean SGPT and SGOT level were more in group B than that of group A. But the rise in mean SGPT and SGOT level was not statistically significant (p>0.05). Rise in BUN was significant (p<0.01) by the 15th day in Group A patients but it did not cross the normal limit. There was not significant (p 0.05) rise in the mean serum creatinine level during treatment in patients of both groups.

Fall in serum Potassium level was significant (p<0.05) at 22nd and 30th day of treatment in group A patients while the fall was not significant (p>0.05) in group B patients. These results suggest that during treatment hepatic and renal markers were not altered significantly which warrant the withdrawal of the drug in both groups. It is highly recommended that serial monitoring of hepatic and renal markers are useful parameters in anti kala-azar therapy.